OM1 has raised $156.0M in total across 3 funding rounds.
OM1's investors include A Capital, Arbor Ventures, Benchmark, Bessemer Venture Partners, Cisco Investments, Citi Ventures, Felix Capital, General Catalyst, L Catterton Growth, Lightspeed Venture Partners, March Capital, NewView Capital.
OM1 is a Boston-based technology company founded in 2015 that builds the OM1 Real-World Data Cloud, a platform combining big clinical data from over 300 million patients, AI, and machine learning to deliver research-grade real-world evidence (RWE) for healthcare stakeholders.[1][2][4][6] It specializes in chronic diseases, personalized medicine, evidence generation, and RWE research, serving pharma, providers, payers, and patients by enabling faster access to precise outcomes data for drug approvals, post-market commitments, trial optimization, and predictive modeling.[1][2][5] Key products include automated data networks, premium datasets, advanced analytics, and precision modeling, with recent growth shown through awards like Frost & Sullivan's 2024 New Product Innovation and 2025 Life Sciences RWE top contender status, plus network expansions adding 500,000 neurology patients in August 2025.[6][7]
OM1 was founded in 2015 in Boston, Massachusetts, emerging as a pioneer in reimagining healthcare measurement through real-world data and AI integration.[2] While specific founders are not detailed in available sources, the company originated from a focus on transforming how outcomes are measured and delivered, starting with the development of the OM1 Real-World Data Cloud to address gaps in clinical data usability.[1][5] Early traction came from building automated data networks and specialty datasets in chronic diseases, evolving into a full-stack platform with billions of data points, AI-driven predictives, and tools for FDA submissions and commercialization support; pivotal moments include recent expansions like the high-quality Rheumatoid Arthritis dataset rating and neurology network growth in 2025.[1][6][7]
OM1 stands out in the RWE space through these key strengths:
OM1 rides the AI-powered RWE and personalized medicine wave, capitalizing on exploding demand for real-world data amid regulatory shifts like FDA's emphasis on RWE for approvals and post-market evidence.[1][6] Timing is ideal as healthcare shifts from siloed datasets to integrated, predictive platforms—OM1's 300+ million patient cloud and cognitive tech address market forces like rising trial costs, payer scrutiny, and precision therapy needs, enabling earlier diagnosis via ML and better provider patterns prediction.[1][4] It influences the ecosystem by setting benchmarks in data quality (e.g., top-rated RA dataset) and innovation, partnering with global pharma like Lilly, fostering scalable networks, and pushing RWE into practice for improved patient outcomes and research efficiency.[6][7]
OM1 is poised for accelerated growth through ongoing network expansions, AI enhancements like digital phenotyping, and deepening pharma collaborations, with trends like regulatory RWE adoption and multimodal data integration (e.g., EMR harmonization, imaging) shaping its path.[6][7] Expect influence to evolve via tools like OM1 Aspen for automated evidence and webinars on AI strategies, potentially capturing more market share in neurology, RA, and beyond as 2025 awards signal momentum. This positions OM1 as a transformative force, directly advancing the healthcare measurement revolution it set out to ignite.[1][5][6]
OM1 has raised $156.0M across 3 funding rounds. Most recently, it raised $85.0M Series D in July 2021.
